Sera Prognostics, Inc., (SERA): Price and Financial Metrics Recent IPO


Sera Prognostics, Inc., (SERA): $7.90

-0.28 (-3.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SERA Stock Price Chart Interactive Chart >

Price chart for SERA

SERA Price/Volume Stats

Current price $7.90 52-week high $15.50
Prev. close $8.18 52-week low $7.61
Day low $7.78 Volume 72,300
Day high $8.50 Avg. volume 108,640
50-day MA $0.00 Dividend yield N/A
200-day MA $0.00 Market Cap 231.42M

Sera Prognostics, Inc., (SERA) Company Bio


Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.


SERA Latest News Stream


Event/Time News Detail
Loading, please wait...

SERA Latest Social Stream


Loading social stream, please wait...

View Full SERA Social Stream

Latest SERA News From Around the Web

Below are the latest news stories about Sera Prognostics Inc that investors may wish to consider to help them evaluate SERA as an investment opportunity.

Sera Prognostics to be Added to Russell 2000 Index

SALT LAKE CITY, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that according to a preliminary list of initial public offering (IPO) additions to the Russell indexes, the company will be added to the Russell 2000 Index effective Sept. 20, 2021. “We are pleased to be included in the Russell 2000 Index f

Yahoo | September 20, 2021

Sera Prognostics Appoints Dr. Michael R. Foley as Chief Medical Officer

Dr. Michael R. Foley Sera Prognostics Appoints Dr. Michael R. Foley as Chief Medical Officer SALT LAKE CITY, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Dr. Michael R. Foley has been appointed to the position of Chief Medical Officer beginning in January 2022. Dr. Foley will lead all medical ac

Yahoo | September 15, 2021

Sera Prognostics Announces Publication of Health Economic Analysis Supporting PreTRM® Test-and-Treat Strategy to Improve Maternal and Infant Health

Publication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs Positive impact on preterm births, neonatal intensive care admissions, overall hospital length of stay and a net $54 million reduction in total costs in the analyzed population SALT LAKE CITY, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™, focused on improving maternal and neonatal health by providing i

Yahoo | September 14, 2021

Sera Prognostics to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit

SALT LAKE CITY, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Tuesday, September 21, 2021 at 8:15 a.m. Eastern Time. Gregory C. Critchfield, M.D., M.S., Chairman and CEO, will provide a company update a

Yahoo | September 13, 2021

Sera Prognostics Reports Second Quarter 2021 Financial Results

SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended June 30, 2021. Recent Highlights: Announced peer-reviewed published results of the PREVENT-PTB study, a prospective, randomized controlled intervention trial evaluating clinical utility of Sera

Yahoo | August 30, 2021

Read More 'SERA' Stories Here

SERA Price Returns

1-mo -29.78%
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6975 seconds.